A new Alzheimer’s treatment ‘Leqembi’ is expected to receive approval for marketing in Korea.

The Ministry of Food and Drug Safety (MFDS) is conducting a final assessment of Leqembi (lecanemab), a drug jointly developed by Eisai and Biogen, for marketing approval. Leqembi’s application for approval was submitted last year, indicating an expected approval date in the first half of the year.

The drug will be indicated as a treatment of ‘Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia.’

Leqembi has been shown to reduce the rate of disease progression and to slow cognitive and functional decline through selectively binding